Alignment Healthcare (ALHC) Stock Sinks After Q3 Earnings Margin Crunch

Alignment Healthcare walked into this Q3 2026 print with a reputation as a high growth Medicare Advantage upstart that had finally turned profitable over the past year. The stock did not trade that way today. Shares slumped almost 10% to US$7.27 as investors reacted to a quarter that paired roughly US$1.36b of revenue with a return to loss making territory on basic earnings per share.

For a business priced on a rich P/E multiple and a big long term growth story, the real shock was the squeeze in medical profitability. An adjusted medical benefit ratio of 89.5% and only US$22m of adjusted EBITDA left the market questioning how much of the thesis rests on margins that now look far tighter than the share price did yesterday.

Love Alignment Healthcare's revenue scale but concerned about the pressure on profitability and medical costs this quarter? You may want to consider screening for health insurers with steadier margins and stronger balance sheets using the list of solid balance sheet and fundamentals stocks (25 results).

Q3 2026 Earnings Summary

• Revenue (Q3 2026 vs. Q3 2025): US$1,358.29m vs. US$993.70m (higher top line year on year).
• Net Income/Loss (Q3 2026 vs. Q3 2025): loss of US$8.05m vs. profit of US$3.73m (moved back into the red).
• Basic EPS (Q3 2026 vs. Q3 2025): loss of US$0.04 per share vs. profit of US$0.02 per share (earnings swung back to a per share loss).
• Adjusted Medical Benefit Ratio (MBR, Q3 2026 vs. Q3 2025): 89.5% in Q3 2026 vs. lower internal expectations in the prior-year period (medical costs consumed a larger share of revenue).

Prefer visual charts instead of another dense wall of earnings commentary and medical cost ratios? See Alignment Healthcare's full financial picture, including a clear view of profitability trends, margins, and related metrics in the company report for Alignment Healthcare.

Evaluating Alignment’s Profit Conversion Milestone

The bullish story leans heavily on Alignment Healthcare eventually turning today’s membership base into tomorrow’s earnings engine.

"The main thing that has to go right is that Alignment Healthcare converts its embedded adjusted gross profit potential into realised earnings while managing Medicare Advantage star ratings, regulatory changes, and governance concerns without a material and lasting hit to margins."

Q3 shows that conversion milestone was not met. Adjusted gross profit of US$142m on roughly US$1.36b of revenue produced only US$22m of adjusted EBITDA and a basic EPS loss. Lowered full year adjusted gross profit and EBITDA guidance, alongside an 89.5% adjusted medical benefit ratio, indicates that margin pressure is currently blocking that earnings translation.

Not everyone reads the same price the same way. → See the higher figure this Narrative lands on, and how it gets there.

Alignment Healthcare Bear Case Gets Fresh Support

The bearish view argues that Alignment Healthcare’s growth model is fragile because cost control and cash generation have not kept pace with expansion.

"Despite rapid top-line expansion and improved adjusted EBITDA, the company's consistently thin margins, high medical loss ratios, and negative free cash flow signal that scaling profitably remains elusive; further failures to contain medical costs as it expands geographically could force reliance on additional debt or equity financing, diluting future earnings per share."

Q3 does not disprove that concern. An 89.5% adjusted medical benefit ratio, only US$22m of adjusted EBITDA and reduced full-year profit guidance highlight that medical cost pressure is still limiting earnings conversion, even as membership and revenue rise.

Hunt For Mispriced Growth Stories

Alignment Healthcare shows that strong revenue without firm medical margins can still hurt a stock. The real opportunity is in finding stocks that could be undervalued before the market corrects them.

• Company 1 - 21% below our estimate - targets rising AI and data traffic by expanding higher value photonics packaging capacity for hyperscalers and telecom customers.
• Company 2 - 22% below our estimate - feeds the surge in hyperscale data center builds as power-focused construction projects convert a swollen backlog into multi-year installation work.
• Company 3 - 47% below our estimate - pours capital into AI infrastructure so its ad tools and AI-enabled messaging can tighten targeting and deepen business spending.

Those are three of them. See every one of the 29 undervalued companies on it →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com